Welcome to our dedicated page for Wearable Devices Ltd. SEC filings (Ticker: WLDS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Wearable Devices Ltd. (WLDS) SEC filings page on Stock Titan aggregates the company’s public reports as a foreign private issuer, giving investors structured access to its regulatory disclosures. Wearable Devices files primarily on Form 6-K under the Securities Exchange Act of 1934, and these reports often attach press releases or transaction documents that explain key corporate and financing events.
Recent 6-K filings describe registered direct offerings of ordinary shares and pre-funded warrants, concurrent private placements of ordinary warrants, and an at-the-market sales agreement for ordinary shares. These filings outline terms such as offering structures, use of registration statements on Form F-3, warrant exercise conditions, lock-up provisions and commission arrangements with placement agents or sales agents. Other 6-Ks cover matters like annual and special general meetings, amendments to the company’s compensation policy, and increases in authorized share capital through changes to its articles of association.
For those analyzing WLDS, the filings also reference clinical and technology milestones when they are furnished as exhibits, such as the neurorehabilitation pilot with Soroka University Medical Center and grant support from the Israel Innovation Authority. While detailed financial statements are not included in the excerpts provided here, the 6-K framework allows the company to incorporate press releases and legal opinions by reference into existing registration statements on Form F-3 and Form S-8.
On Stock Titan, users can review these WLDS filings in chronological order and use AI-powered summaries to interpret complex legal and transactional language. The platform highlights essential elements of each report—such as the nature of an offering, key conditions, and referenced exhibits—so readers can more quickly understand how each filing relates to Wearable Devices’ capital structure, governance decisions and product-related disclosures.
Wearable Devices Ltd. filed a post-effective amendment to register up to 33,644 ordinary shares issuable upon exercise of outstanding IPO Warrants and Underwriter’s Warrants originally issued in the company’s 2022 IPO. The filing covers 32,863 IPO Warrant shares and 781 Underwriter’s Warrant shares.
The company states it would receive up to $15.8 million in net proceeds if all IPO Warrants are exercised (assuming the adjusted $480.00 exercise price) and up to $995 thousand if all Underwriter’s Warrants are exercised. Shares outstanding were 3,597,740 Ordinary Shares as of March 22, 2026.
Wearable Devices Ltd. director Ilana Lurie filed an initial ownership report showing her equity stake in the company. She directly holds 37,500 Ordinary Shares. This amount includes 7,500 shares issuable from 2,500 restricted share units (RSUs) that begin vesting on October 10, 2026 and then in equal monthly installments through October 10, 2028, and 28,333 shares issuable from RSUs vesting in equal monthly installments of 833 shares through January 1, 2029, with each RSU representing one Ordinary Share.
She also holds a stock option covering 83 Ordinary Shares at an exercise price of 316.8000, which was granted on November 30, 2023, vests in monthly installments after an initial vesting on August 23, 2024, and expires on November 30, 2033.
Wearable Devices Ltd. Chief Marketing Officer Barel Shmuel filed an initial Form 3 showing his beneficial ownership in the company. The filing reports direct ownership of 31,333 Ordinary Shares, plus stock options and restricted share units that may convert into additional shares over time.
He holds stock options over 593 Ordinary Shares at an exercise price of 0.7200 per share expiring on November 1, 2031, and options over 104 Ordinary Shares at 316.8000 per share expiring on November 30, 2033. Footnotes indicate 3,500 RSUs vesting in monthly installments of 583 shares through September 10, 2026 and 21,407 RSUs vesting in monthly installments of 630 shares through January 1, 2029, each RSU representing one Ordinary Share.
Wearable Devices Ltd. director Nir Yaacov filed an initial insider ownership report on Form 3. The filing lists him as a director of the company but does not report any share transactions or derivative positions, indicating this is a baseline disclosure rather than a trading event.
Wearable Devices Ltd. Chief Financial Officer Mualem Alon filed an initial Form 3 reporting his existing equity position. He directly holds 52,083 Ordinary Shares and has stock options covering 417 shares at an exercise price of $0.7200 expiring on January 23, 2032 and 83 shares at $316.8000 expiring on November 30, 2033. Footnotes also describe RSU awards for 5,000 Ordinary Shares vesting monthly through September 10, 2026 and 37,778 Ordinary Shares vesting monthly through January 1, 2029, each RSU representing one Ordinary Share.
Wearable Devices Ltd. Chief Operating Officer Tamar Fleisher filed an initial ownership report showing direct holdings in the company’s ordinary shares and equity awards. The filing lists 23,667 Ordinary Shares, which include RSUs for 2,500 shares vesting in monthly installments of 417 shares through September 10, 2026 and RSUs for 16,056 shares vesting in monthly installments of 472 shares through January 1, 2029. Fleisher also holds stock options over 125 ordinary shares at an exercise price of 158.4000, expiring on December 15, 2032, and options over 63 ordinary shares at an exercise price of 316.8000, expiring on November 30, 2033. These entries reflect existing positions rather than new market purchases or sales.
Wearable Devices Ltd. files a post-effective amendment registering up to 2,904,500 Ordinary Shares for resale by a selling shareholder; these shares are issuable upon exercise of warrants previously issued in private placements.
The prospectus states the Company will not receive proceeds from resale by the selling shareholder, but could receive up to $18.6 million if the warrants are exercised for cash (assuming full exercise). The filing reports 3,597,740 Ordinary Shares outstanding prior to the offering and a pro forma total of 6,502,240 Ordinary Shares if all registered warrants are exercised for cash.
Wearable Devices Ltd. files its annual Form 20-F, describing a neural wristband interface business now shifting from R&D to commercialization, including its Mudra Band for Apple devices. The company reports 2,882,802 ordinary shares outstanding as of December 31, 2025 and an accumulated deficit of approximately $37.2 million.
Management discloses prior going concern doubts and expects substantial ongoing losses, emphasizing reliance on product sales and additional capital raises, including past dependence on Armistice Capital. The filing highlights intense competition from large technology companies, long B2B licensing cycles without signed licenses to date, multiple recent reverse share splits to maintain Nasdaq listing, and extensive operational, data privacy, cybersecurity and AI-related risks.